211 related articles for article (PubMed ID: 22933706)
21. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
23. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
[TBL] [Abstract][Full Text] [Related]
25. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
[TBL] [Abstract][Full Text] [Related]
26. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
27. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.
Stühmer T; Chatterjee M; Hildebrandt M; Herrmann P; Gollasch H; Gerecke C; Theurich S; Cigliano L; Manz RA; Daniel PT; Bommert K; Vassilev LT; Bargou RC
Blood; 2005 Nov; 106(10):3609-17. PubMed ID: 16081689
[TBL] [Abstract][Full Text] [Related]
28. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells.
Shen H; Moran DM; Maki CG
Cancer Res; 2008 Oct; 68(20):8260-8. PubMed ID: 18922897
[TBL] [Abstract][Full Text] [Related]
29. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
30. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
31. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.
Endo S; Yamato K; Hirai S; Moriwaki T; Fukuda K; Suzuki H; Abei M; Nakagawa I; Hyodo I
Cancer Sci; 2011 Mar; 102(3):605-13. PubMed ID: 21205074
[TBL] [Abstract][Full Text] [Related]
32. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
33. MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines.
Tsao CC; Corn PG
Cancer Biol Ther; 2010 Dec; 10(12):1315-25. PubMed ID: 20953142
[TBL] [Abstract][Full Text] [Related]
34. Chk2 mediates RITA-induced apoptosis.
de Lange J; Verlaan-de Vries M; Teunisse AF; Jochemsen AG
Cell Death Differ; 2012 Jun; 19(6):980-9. PubMed ID: 22158418
[TBL] [Abstract][Full Text] [Related]
35. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
Issaeva N; Bozko P; Enge M; Protopopova M; Verhoef LG; Masucci M; Pramanik A; Selivanova G
Nat Med; 2004 Dec; 10(12):1321-8. PubMed ID: 15558054
[TBL] [Abstract][Full Text] [Related]
36. HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Jones RJ; Baladandayuthapani V; Neelapu S; Fayad LE; Romaguera JE; Wang M; Sharma R; Yang D; Orlowski RZ
Blood; 2011 Oct; 118(15):4140-9. PubMed ID: 21844567
[TBL] [Abstract][Full Text] [Related]
37. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
38. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.
Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
Clin Cancer Res; 2013 Sep; 19(18):5092-103. PubMed ID: 23864164
[TBL] [Abstract][Full Text] [Related]
39. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
40. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas.
Sosin AM; Burger AM; Siddiqi A; Abrams J; Mohammad RM; Al-Katib AM
J Hematol Oncol; 2012 Sep; 5():57. PubMed ID: 22989009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]